Allos’ Brain Cancer Drug Fails Phase 3 Trials
Allos had a disappointing failure in phase III for efaproxyn for treatment of brain cancer that originated from breast cancer.
Allos’ Brain Cancer Drug Flops in Phase 3 - Health - RedOrbit:
In typical upbeat company fashion, they said they were disappointed but immediately started proclaiming their pipeline and how promising it is. This seems to be very common these days. I know there is the need to proclaim \the positive and negate the negatives but it seems to be out of balance in many of these sorts of press releases.
Technorati Tags: Allos
Related Posts:
Bookmark it with:
| 
del.icio.us
| 
Digg it
| 
Furl
| 
Simpy
| 
Spurl
| 
My Yahoo!
|
